A 2.33 cm/yr gain in annualized growth velocity against placebo — with p<0.0001 — is a larger signal than most skeletal dysplasia trials produce, and it lands in a condition where no approved therapy has ever existed. Hypochondroplasia affects roughly 1 in 15,000 to 40,000 births and is frequently underdiagnosed precisely because its phenotype is milder than achondroplasia. That clinical ambiguity made trial design genuinely difficult: enrollment required rigorous genetic and radiological confirmation in a heterogeneous population, and getting 80 children into CANOPY-HCH-3 across a rare, variable condition is not a small logistical achievement.
The arm span result deserves more attention than it’s getting. Arm span improvement reached statistical significance (p=0.004) as a prespecified secondary endpoint — not a post-hoc addition. In achondroplasia research, proximal limb disproportionality is tied directly to functional limitations: reaching overhead, personal hygiene, operating standard equipment. The fact that vosoritide moved this measure in hypochondroplasia, where the skeletal phenotype is less extreme, suggests the CNP analog pathway is doing real biomechanical work, not just nudging height Z-scores. That distinction will matter when BioMarin presents full data at whatever medical conference it selects — the arm span trajectory over 52 weeks will tell reviewers whether the growth is proportionate or concentrated in a single anatomical segment.
The regulatory path is straightforward on paper. The sNDA submission is planned for Q3 2026, which means FDA review would likely extend into mid-2027 under standard timelines. The agency’s accelerated approval for achondroplasia — still awaiting full conversion, with BioMarin’s confirmatory sNDA filed only in April 2026 — creates a subtle complication: two parallel vosoritide sNDA reviews running simultaneously. FDA has not historically stumbled over this structure, but it adds procedural weight to an already busy PDUFA calendar for BioMarin. EMA and regional submissions follow in sequence, meaning ex-US access lags further.
The single marker worth watching is the height Z-score trajectory in the long-term extension study. A 52-week improvement in AGV is mechanistically compelling, but height Z-score normalization over two to three years — or its absence — will determine whether payers classify this as disease-modifying therapy or a growth-rate adjunct, and that classification drives reimbursement architecture for a drug already priced well above six figures annually in achondroplasia.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
